Sinopec Capital and Meinian Onehealth both invested in the biotech research product maker as it prepares for an initial public offering.

China-based life sciences product developer CapitalBio Technology has raised more than RMB800m ($113m) from investors including oil and gas supplier Sinopec and healthcare services provider Meinian Onehealth, DealStreetAsia reported yesterday. Guangzhou Boyi Architectural Design Institute put up $57m to lead the round, which also featured New Alliance Capital, Red Horse Investments Group, Xin Dig Capital…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.